Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Incesu, RB; Barletta, F; Tappero, S; Piccinelli, ML; Garcia, CC; Morra, S; Scheipner, L; Tian, Z; Saad, F; Shariat, SF; Ahyai, S; Longo, N; Chun, FKH; de, Cobelli, O; Terrone, C; Briganti, A; Tilki, D; Graefen, M; Karakiewicz, PI.
Survival differences in non-seminoma testis cancer patients according to race/ethnicity.
Cancer Epidemiol. 2024; 89:102538 Doi: 10.1016/j.canep.2024.102538
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Ahyai Sascha; Scheipner Lukas
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: BACKGROUND: Historic evidence suggests that non-Caucasian race/ethnicity predisposes to higher testis cancer-specific mortality (CSM) in non-seminoma. However, it is unknown, whether higher CSM in non-Caucasians applies to Hispanics or Asians or African-Americans, or all of the above groups. In contemporary patients, we tested whether CSM is higher in these select non-Caucasian groups than in Caucasians, in overall and in stage-specific comparisons: stage I vs. stage II vs. stage III. METHODS: The Surveillance, Epidemiology, and End Results (SEER) database (2004 -2019) was used. Kaplan-Meier plots and multivariable Cox regression models tested the effect of race/ethnicity on CSM after stratification for stage (I vs. II vs. III) and adjustment for prognosis groups in stage III. RESULTS: In all 13,515 non-seminoma patients, CSM in non-Caucasians was invariably higher than in Caucasians. In stage-specific analyses, race/ethnicity represented an independent predictor of CSM in Hispanics in stage I (HR 1.8, p = 0.004), stage II (HR 2.2, p = 0.007) and stage III (HR 1.4, p < 0.001); in African-Americans in stage I (HR 3.2; p = 0.007) and stage III (HR 1.5; p = 0.042); and in Asians in only stage III (HR 1.6, p = 0.01). CONCLUSIONS: In general, CSM is higher in non-Caucasian non-seminoma patients. However, the CSM increase differs according to non-Caucasian race/ethnicity groups. Specifically, higher CSM applies to all stages of non-seminoma in Hispanics, to stages I and III in African-Americans and only to stage III in Asians. These differences are important for individual patient management, as well as for design of prospective trials.
Find related publications in this database (using NLM MeSH Indexing): Humans - administration & dosage; Male - administration & dosage; Ethnicity - administration & dosage; Proportional Hazards Models - administration & dosage; Prospective Studies - administration & dosage; SEER Program - administration & dosage; Testicular Neoplasms - administration & dosage; White - administration & dosage; Survival - administration & dosage; Racial Groups - administration & dosage; Healthcare Disparities - administration & dosage
Find related publications in this database (Keywords): Testis cancer; Non-seminoma; Survival; Race/ethnicity; IGCCCG